Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Letrozole 2.5mg Clear all
Completed Phase 2 Interventional Results available

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

NCT02040857
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
10
States / cities
San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

NCT01919229
View directory record Official record
Conditions
Early Breast Cancer
Interventions
LEE011 (ribociclib), letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Fayetteville, Arkansas • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

NCT01248494
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
BEZ235, BKM 120, Letrozole, BKM120
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 18, 2026, 9:51 AM EDT
Active, not recruiting Phase 1 Interventional

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

NCT04895761
View directory record Official record
Conditions
Breast Cancer
Interventions
DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg, XRT 10Gy x2
Biological · Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional

Combined Immunotherapies in Metastatic ER+ Breast Cancer

NCT04563507
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg
Radiation · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

NCT04568616
View directory record Official record
Conditions
Breast Cancer, ER Positive Breast Cancer
Interventions
Letrozole 2.5mg
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

NCT04129216
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Letrozole, Exemestane, Blueprint, Mammaprint
Drug · Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Avastin, Hormonal therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

NCT03219476
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD-0332991, Letrozole, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
136
States / cities
Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

NCT00648063
View directory record Official record
Conditions
Healthy
Interventions
Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

NCT06139107
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Mridula George, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT01797523
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin, Letrozole, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
6
States / cities
Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Pilot of Letrozole for Uterine Myomas

NCT02470741
View directory record Official record
Conditions
Leiomyoma, Uterine Fibroids
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 18, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib and Letrozole to Treat Endometrial Cancer

NCT04393285
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

NCT02228681
View directory record Official record
Conditions
Advanced, Persistent, or Recurrent Endometrial Cancer
Interventions
Everolimus, Tamoxifen, Letrozole, Medroxyprogesterone Acetate
Drug
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
26
States / cities
Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

NCT00107016
View directory record Official record
Conditions
Breast Neoplasm
Interventions
RAD001, Letrozole 2.5mg, Letrozole 2.5mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Early Phase 1 Interventional

Study of Letrozole in Recurrent Gliomas

NCT03122197
View directory record Official record
Conditions
Brain Tumor
Interventions
Letrozole Oral Tablet, Temozolomide
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Interventions
Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg, Tamoxifen
Drug
Lead sponsor
Irada Ibrahim-zada
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 9:51 AM EDT
Not listed No phase listed Observational

Aromatase Inhibitor Clinical Trial

NCT00228956
View directory record Official record
Conditions
Breast Cancer
Interventions
pharmacodynamic analysis
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
40 Years to 70 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 18, 2026, 9:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prescription of Letrozole for Uterine Myoma

NCT06143631
View directory record Official record
Conditions
Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
Interventions
Letrozole 2.5mg, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 53 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 9:51 AM EDT